1 min read
XTL Biopharmaceuticals Posts $0.00 GAAP EPS for First Half
Cash and cash equivalents were approximately $1.80 million at June 30, 2026, up from approximately $0.08 million on Dec. 31, 2025.

XTL Biopharmaceuticals Ltd. posted first-half GAAP earnings per share of $0.00.
Cash and cash equivalents totaled approximately $1.80 million on June 30, 2026, compared with approximately $0.08 million on Dec. 31, 2025.